Results 161 to 170 of about 11,503 (243)

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

Design and validation of a ribosome display library for synthetic nanobody selection. [PDF]

Adv Biotechnol (Singap)
Gu W, Li Y, Hong J, Yue Z, Zhang Y, Fan S, Shen Z, Li T, Li D.   +8 more
europepmc   +1 more source

Applications and limitations of AI tools in enzyme design

Protein Science, Volume 35, Issue 8, August 2026.
Abstract Enzymes catalyze various different chemical reactions often with high efficiency and selectivity compared to synthetic catalysts. Advances in protein engineering over the past decades have allowed researchers to design enzymes, improving their catalytic performance and adapting them for specific or entirely novel chemical reactions.
Rosa Teijeiro‐Juiz, Nina Egeler, Grzegorz Jamróg, Marion Ringel, Thomas Brück, Bruno Di Geronimo, Bernhard Loll   +6 more
wiley   +1 more source

Chelator‐Free Radiometal Labeling Inside Engineered Affibodies

Angewandte Chemie, Volume 138, Issue 30, 20 July 2026.
Affibodies are compact and robust three‑helix binders used in imaging and therapy. Engineering a triple‑cysteine motif into their core enables chelator‑free binding of important radiometals, like Bi(III), Pb(II), In(III), and Ga(III) with rapid uptake and exceptional stability.
Lani J. Davies, Upamali Somathilake, Santhanalaxmi Kumaresan, Frank Bruchertseifer, Alfred Morgenstern, Sarah Spreckelmeyer, Christoph Nitsche   +6 more
wiley   +2 more sources

Nanobody targeting glycan cap confers broad orthoebolavirus neutralization. [PDF]

Virol Sin
Zhang X, Liao Y, Liu X, Zhou J, Gao P, Dong X, Pan S, Duan H, Liu J, Chi X, Yang W.   +10 more
europepmc   +1 more source

The Pharmacology of the SLC15A4‐TASL Complex, an Emerging Target for the Treatment of Lupus

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT SLC15A4 is a member of the solute carrier superfamily that has been strongly linked to the pathogenesis of the auto‐immune disease SLE. The endo‐lysosomally localized SLC15A4 has traditionally been considered a proton‐dependent histidine and peptide transporter, but has also been shown to facilitate TLR7, 8, and 9 induced IFN‐alpha signaling ...
Alex L. Wilkinson, Dillon Popat, Kathy Sengmany, Miguel C. Silva, Steven J. Charlton, Charles S. Lay   +5 more
wiley   +1 more source

Dissecting the disconnect between circuit activation and dominant adaptive evolution in cytoplasmic phage-assisted continuous evolution (PACE) of an EGFR nanobody. [PDF]

Front Bioeng Biotechnol
Chuang JN, Purcell J, Sangalli L, Rosenbluh J, Knott GJ, Corrie S, Garnier G.   +6 more
europepmc   +1 more source

Engineered Bacterial Membranes as Next‐Generation Platforms for Cancer Immunotherapy

Small Science, Volume 6, Issue 8, August 2026.
Engineered bacterial membrane platforms, including outer membrane vesicles, bacterial ghosts, genetically engineered membranes, and hybrid bacterial–tumor membranes, integrate tumor antigen presentation with intrinsic immune stimulation. These platforms promote dendritic‐cell activation, T‐cell priming, pyroptosis, and synergistic responses with ...
Hafiza Aasia Malik, Urooj Yousaf Virk, Mohamed Salah Attia, Jenny Wilson, Ming Wei   +4 more
wiley   +1 more source